SCHEMBL5757635

SCHEMBL5757635

COc1ccc(CSc2nc3ccc(S(=O)(=O)N[C@@H](C(=O)O)C(C)C)cc3s2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
LMNA P02545 2/20 0.53
MAPK1 P28482 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MMP9 P14780 5/20 0.53
MMP2 P08253 4/20 0.53
MMP13 P45452 3/20 0.53
MMP1 P03956 1/20 0.53
MMP3 P08254 1/20 0.53
MMP7 P09237 1/20 0.53
MMP8 P22894 1/20 0.53
ADAMTS4 O75173 2/20 0.52
ALDH1A1 P00352 2/20 0.49
GAA P10253 1/20 0.49
THRB P10828 1/20 0.49
MMP12 P39900 3/20 0.47
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5806540 0.91 MMP9 (0.54) MAPTLMNAMAPK1L3MBTL1MMP9
SCHEMBL5758844 0.90 MAPT (0.56) MAPTLMNAMMP13ADAMTS4ALDH1A1
SCHEMBL5754134 0.89 HTT (0.52) MAPTMMP9MMP2MMP13MMP1
SCHEMBL6966735 0.86 MMP13 (0.55) MMP9MMP2MMP13MMP1MMP3
SCHEMBL5756259 0.84 ALOX15 (0.53) MMP13ALDH1A1GAAMMP12MEN1
SCHEMBL6980252 0.83 MAPT (0.52) MAPTLMNAMAPK1L3MBTL1ALDH1A1
SCHEMBL5759318 0.82 ALOX15 (0.52) MMP13ALDH1A1GAAMMP12MEN1
SCHEMBL5756019 0.82 MAPT (0.53) MAPTLMNAMMP9MMP2MMP13
SCHEMBL5757339 0.81 PKM (0.56) LMNAMMP9MMP2MMP13ALDH1A1
SCHEMBL5754971 0.81 ALOX15 (0.50) MMP13ALDH1A1GAAMMP12MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 MAPT 4046/4885LMNA 1839/4885MAPK1 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.